160 related articles for article (PubMed ID: 22331549)
1. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.
Kunz PL; He AR; Colevas AD; Pishvaian MJ; Hwang JJ; Clemens PL; Messina M; Kaleta R; Abrahao F; Sikic BI; Marshall JL
Invest New Drugs; 2012 Dec; 30(6):2364-70. PubMed ID: 22331549
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of oral ixabepilone in patients with advanced solid tumors.
Deeken JF; Marshall JL; Pishvaian MJ; Hwang J; Ahlers CM; Clemens PL; Parker SM; Iacono L; LoRusso PM
Cancer Chemother Pharmacol; 2014 May; 73(5):1071-8. PubMed ID: 24663504
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of dasatinib and ixabepilone in patients with solid tumors.
Herbolsheimer P; Kapoor R; Smith KL; Perry D; Verma N; Veytsman I; Jelinek J; Swain SM
Invest New Drugs; 2013 Feb; 31(1):92-8. PubMed ID: 22392508
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.
Konner J; Grisham RN; Park J; O'Connor OA; Cropp G; Johnson R; Hannah AL; Hensley ML; Sabbatini P; Mironov S; Danishefsky S; Hyman D; Spriggs DR; Dupont J; Aghajanian C
Invest New Drugs; 2012 Dec; 30(6):2294-302. PubMed ID: 22072399
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
Widemann BC; Goodspeed W; Goodwin A; Fojo T; Balis FM; Fox E
J Clin Oncol; 2009 Feb; 27(4):550-6. PubMed ID: 19075272
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
[TBL] [Abstract][Full Text] [Related]
14. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
Zhang P; Sun M; Qiu R; Tang L; Dou G; Xu B
Cancer Chemother Pharmacol; 2011 Oct; 68(4):971-8. PubMed ID: 21305287
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.
Calvo E; Vermorken JB; Hiret S; Rodon J; Cortes J; Senellart H; Van den Brande J; Dyck J; Pétain A; Ferre P; Bennouna J
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1467-75. PubMed ID: 22382883
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
[TBL] [Abstract][Full Text] [Related]
20. Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
Luu T; Kim KP; Blanchard S; Anyang B; Hurria A; Yang L; Beumer JH; Somlo G; Yen Y
Breast Cancer Res Treat; 2018 Jan; 167(2):469-478. PubMed ID: 28956187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
